US funding bill forces drugmakers, including Novartis, to rethink pricing and market strategy

U.S. funding bill pushes drugmakers to rethink pricing and product strategy

A provision in the recent U.S. government funding bill aimed at lowering prescription drug costs is driving fresh strategic reassessments across the pharmaceutical sector, with global groups such as Novartis monitoring policy fallout closely. The measure signals renewed regulatory momentum to curb drug prices, prompting executives and policy teams to evaluate how launch pricing, rebate structures and contracting approaches with payers will need to change. Industry officials now face a compressed timetable to translate legislative language into operational choices.

The provision is shifting internal emphasis from primarily revenue-maximisation at launch toward demonstrating measurable, short‑term value to health systems and insurers. Companies are exploring broader use of value‑based contracts, outcomes‑based pricing and expanded real‑world evidence programmes to support negotiations with payers. Observers also note companies may accelerate life‑cycle management tactics and prioritise assets with clear, demonstrable clinical benefit to limit exposure to price‑reduction measures tied to the funding bill.

For Novartis, the policy development intersects with its diversified business model, spanning patented medicines, generics and biosimilars. The group is positioned to leverage its scale in manufacturing and regulatory experience in biosimilars while also needing to safeguard margins on high‑value specialty drugs. Novartis is likely to refine its market access strategies, increase emphasis on post‑launch evidence generation and consider geographic pricing differentiation as governments and payers press for lower net prices and greater affordability.

Eli Lilly’s strong recent results underscore the competitive intensity in major therapy areas and reinforce industry focus on commercial performance and pipeline prioritisation. Drugmakers are watching peers’ sales trends and clinical readouts closely as benchmarks for payer willingness to accept premium pricing under tougher policy scrutiny.

The policy push comes amid a broader environment of heightened government intervention across industries. Washington is convening international talks on critical minerals and Europe is pursuing partnerships on strategic supplies, reflecting a wider appetite for industrial policy. For pharmaceuticals, that translates into sustained regulatory attention and the need for companies like Novartis to align product, access and policy strategies to a more interventionist landscape.